These recurrent fusion genes prevalent in prostate cancer are formed by fusion of the promoter and 5′-untranslated region (UTR, exon 1 or 2) of the androgen-regulated prostate-specific transmembrane protease serine 2 gene (TMPRSS2) with the translated regions of members of erythroblastosis virus E26 transforming sequence (ETS) family of transcription factors, ERG and ETV1 [1]. The gene discussed is ERG; the disease is prostate cancer.